Zurcher Kantonalbank Zurich Cantonalbank Boosts Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 37.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,199 shares of the company’s stock after buying an additional 7,888 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Vaxcyte were worth $2,390,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PCVX. Amalgamated Bank raised its stake in Vaxcyte by 8.6% during the 3rd quarter. Amalgamated Bank now owns 4,081 shares of the company’s stock valued at $466,000 after purchasing an additional 322 shares during the period. Principal Financial Group Inc. raised its stake in Vaxcyte by 186.2% during the 3rd quarter. Principal Financial Group Inc. now owns 52,702 shares of the company’s stock valued at $6,022,000 after purchasing an additional 34,287 shares during the period. Atria Investments Inc bought a new stake in Vaxcyte during the 3rd quarter valued at approximately $286,000. Sumitomo Mitsui Trust Group Inc. raised its stake in Vaxcyte by 24.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 5,649 shares of the company’s stock valued at $646,000 after purchasing an additional 1,120 shares during the period. Finally, Oppenheimer & Co. Inc. bought a new stake in Vaxcyte in the 3rd quarter worth approximately $510,000. Institutional investors own 96.78% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. The Goldman Sachs Group assumed coverage on Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective on the stock. Guggenheim reaffirmed a “buy” rating and issued a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday, March 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, February 26th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Stock Performance

NASDAQ PCVX opened at $74.37 on Monday. The company has a market cap of $9.58 billion, a P/E ratio of -16.17 and a beta of 1.02. The business’s 50 day moving average price is $82.24 and its 200-day moving average price is $94.48. Vaxcyte, Inc. has a fifty-two week low of $58.10 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.14. As a group, equities analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Insider Activity at Vaxcyte

In related news, COO Jim Wassil sold 8,000 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the transaction, the chief operating officer now owns 154,931 shares in the company, valued at $11,351,794.37. The trade was a 4.91 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Teri Loxam sold 6,250 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the transaction, the director now owns 7,175 shares of the company’s stock, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 54,250 shares of company stock worth $4,550,258 in the last quarter. 3.10% of the stock is owned by company insiders.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.